Table 2.
Newly approved drugs targeting class B GPCRs in the past 3 years
| Drug | Brand name (manufacturer) | Indication | Target | GPCR class | FDA approval date |
|---|---|---|---|---|---|
| Erenumab-aooe | Aimovig (Amgen) | Migraine (prevention) | CALCRL | B1, peptide, calcitonin | 05/17/2018 |
| Ubrogepant | Ubrelvy (Allergan) | Migraine | CALCRL | B1, peptide, calcitonin | 12/23/2019 |
| Rimegepant | Nurtec ODT (Biohaven Pharm) | Migraine | CALCRL | B1, peptide, calcitonin | 02/27/2020 |
| Eptinezumab-jjmr | Vyepti (Lundbeck) | Migraine (prevention) | CALCRL | B1, peptide, calcitonin | 02/21/2020 |
| Semaglutide (injection) | Ozempic (Novo Nordisk) | Type 2 diabetes mellitus | GLP-1R | B1, peptide, glucagon-like peptide-1 | 12/05/2017 |
| Semaglutide (oral) | Rybelsus (Novo Nordisk) | Type 2 diabetes mellitus | GLP-1R | B1, peptide, glucagon-like peptide-1 | 09/20/2019 |
The drugs listed above were identified manually from Drugs@FDA original NDA and BLA database (data extracted from August 2017 to June 2020) and cross-referenced with Drugbank,20 IUPHAR, and ChemBL databases
CALCRL (CGRPR) calcitonin gene-related peptide type 1 receptor